Innovating Works

Myeloma Patients Europe AISBL

Desconocido
SISAQOL-IMI: Establishing international standards in the analysis of patient reported outcomes and health related... MYELOMA PATIENTS EUROPE AISBL participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials. It is genera...
2020-11-09 - 2024-12-31 | Financiado
CARAMBA: SLAMF7 CAR T cells prepared by Sleeping Beauty gene transfer for immunotherapy of multiple myeloma... MYELOMA PATIENTS EUROPE AISBL participó en un H2020: H2020-SC1-2016-2017 CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy....
2017-11-22 - 2023-06-30 | Financiado
MMpredict: Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectivenes... MYELOMA PATIENTS EUROPE AISBL participó en un H2020: H2020-FTIPilot-2015-1 The consortium aims to commercialise the MMpredictor as a personalised medicine tool that predicts the most effective treatment strategy for...
2016-10-30 - 2020-10-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.